TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06369285: A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Sponsor: Puma Biotechnology, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 225 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT06369285 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06369285 Rescue Dossier →